Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is one of the evaluation methods of anti-angiogenic agents, such as anti-VEGF antibody and tyrosine kinase inhibitor, clinically (Morgan et al, 2003; O’Connor et al, 2007) and preclinically (Marzola et al, 2004; Nakamura et al, 2006; Bradley et al, 2009), by calculating pharmacokinetic parameters, including fractional plasma volume (vp) and the volume transfer constant (Ktrans) from the enhancement of tumour signal intensity by gadolinium (Gd) contrast agent (Tozer, 2003; Kiessling et al, 2007). Here, VEGFA is linked to neoplasm.